1. In Vivo Assessment of VCAM-1 Expression by SPECT/CT Imaging in Mice Models of Human Triple Negative Breast Cancer.
- Author
-
Montemagno, Christopher, Dumas, Laurent, Cavaillès, Pierre, Ahmadi, Mitra, Bacot, Sandrine, Debiossat, Marlène, Soubies, Audrey, Djaïleb, Loic, Leenhardt, Julien, De Leiris, Nicolas, Dufies, Maeva, Pagès, Gilles, Hernot, Sophie, Devoogdt, Nick, Perret, Pascale, Riou, Laurent, Fagret, Daniel, Ghezzi, Catherine, and Broisat, Alexis
- Subjects
BREAST cancer prognosis ,ANIMAL experimentation ,CELL adhesion molecules ,CELL lines ,COMPUTED tomography ,GENE expression ,HEALTH ,INTRAVENOUS injections ,LUNG tumors ,METASTASIS ,MICE ,TECHNETIUM ,TUMOR markers ,XENOGRAFTS ,BIBLIOGRAPHIC databases ,SINGLE-photon emission computed tomography ,IN vivo studies - Abstract
Recent progress in breast cancer research has led to the identification of Vascular Cell Adhesion Molecule-1 (VCAM-1) as a key actor of metastatic colonization. VCAM-1 promotes lung-metastases and is associated with clinical early recurrence and poor outcome in triple negative breast cancer (TNBC). Our objective was to perform the in vivo imaging of VCAM-1 in mice models of TNBC. The Cancer Genomic Atlas (TCGA) database was analyzed to evaluate the prognostic role of VCAM-1 in TNBC. MDA-MB-231 (VCAM-1+) and control HCC70 (VCAM-1-) TNBC cells were subcutaneously xenografted in mice and VCAM-1 expression was assessed in vivo by single-photon emission computed tomography (SPECT) imaging using
99m Tc-cAbVCAM1-5. Then, MDA-MB-231 cells were intravenously injected in mice and VCAM-1 expression in lung metastasis was assessed by SPECT imaging after 8 weeks. TCGA analysis showed that VCAM-1 is associated with a poor prognosis in TNBC patients. In subcutaneous tumor models,99m Tc-cAbVCAM1-5 uptake was 2-fold higher in MDA-MB-231 than in HCC70 (p < 0.01), and 4-fold higher than that of the irrelevant control (p < 0.01). Moreover,99m Tc-cAbVCAM1-5 uptake in MDA-MB-231 lung metastases was also higher than that of99m Tc-Ctl (p < 0.05).99m Tc-cAbVCAM1-5 is therefore a suitable tool to evaluate the role of VCAM-1 as a marker of tumor aggressiveness of TNBC. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF